Iron supplements

铁补充剂
  • 文章类型: Journal Article
    身体发育和生长受到充足营养的显著影响。搪瓷,牙本质,牙髓是含有铁的组织之一,它被认为是人类健康的必要元素。可用的铁滴的缺点包括味道差和乳牙的黑色变色。在脱钙和低矿化的地区,这种变色更明显。因此,正在努力制造具有更令人愉悦的味道和最小不利影响的铁滴(即,没有或最小的牙齿变色)。脂质体是由磷脂双层制成的微小囊泡,可以包裹亲水性和疏水性药物以提高其有效性并减少副作用(颜色染色)。因此,该研究的目的是比较化妆品材料与小儿脂质体铁补充剂和常规小儿铁补充剂的颜色稳定性。
    LokhandeRS,PJN,DeoghareA,etal.不同铁补充剂对纳米复合修复材料颜色稳定性的影响[J].IntJClinPediatrDent2024;17(3):274-278。
    Physical development and growth are significantly influenced by adequate nutrition. Enamel, dentin, and dental pulp are among the tissues that contain iron, which is regarded as a necessary element for human health. The disadvantages of the available iron drops include bad taste and black discoloration of primary teeth. In areas that are decalcified and hypomineralized, this discoloration is more noticeable. Therefore, efforts are being made to create iron drops that have a more pleasant taste and minimal adverse effects (i.e., no or minimal tooth discoloration). Liposomes are minuscule vesicles made of the bilayer of phospholipids that can encase both hydrophilic and hydrophobic drugs to boost their effectiveness and lessen side effects (color staining). Therefore, the goal of the study is to compare the color stability of cosmetic materials with that of pediatric liposomal iron supplements and regular pediatric iron supplements.
    UNASSIGNED: Lokhande RS, PJ N, Deoghare A,et al. Effect of Different Iron Supplements on Color Stability of Nanocomposite Restorative Materials. Int J Clin Pediatr Dent 2024;17(3):274-278.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:妊娠期贫血在全世界都很常见。在澳大利亚,约17%的育龄非孕妇患有贫血,孕妇的比例增加到25%。这项研究旨在确定新南威尔士州地区妊娠贫血的筛查率。并确定筛查和治疗方案是否遵循推荐的指南.
    方法:这项回顾性研究回顾了2020年1月1日至2020年4月30日在巴瑟斯特医院活产的妇女(n=150)的产前和产后(48小时)数据。人口统计数据,妊娠期贫血的危险因素,产前血液,在妊娠早期(T1)提供的治疗,两个(T2)和三个(T3),记录产后并发症。使用描述性统计将这些与澳大利亚红十字会指南(ARCG)进行比较。
    结果:在有筛查数据的女性中(n=103),他们大多年龄在20-35岁(79.6%),23.3%的人肥胖,97.1%的人缺铁,17%为贫血,只有少数(5.3%)完成了ARCG建议的全面妊娠筛查,而大多数仅完成了部分筛查,特别是T1地区的Hb水平(56.7%)。T2(44.7%)和T3(36.6%)。口服铁的依从性基本上没有记录在案,但是便秘是女性常见的副作用。14.0%的女性服用静脉铁,大约比建议的费率高1.75倍。
    结论:本研究提供了有关妊娠期贫血筛查和治疗指南依从性的有用信息。我们确定需要改善各种卫生提供者之间的文件和沟通,以确保充分的产前护理,以防止怀孕期间的产妇并发症。这将改善病人护理,并鼓励产妇护理的进一步发展,缩小农村卫生差距。
    BACKGROUND: Anaemia during pregnancy is common worldwide. In Australia, approximately 17% of non-pregnant women of reproductive age have anaemia, increasing to a rate of 25% in pregnant women. This study sought to determine the rate of screening for anaemia in pregnancy in regional New South Wales, and to determine whether screening and treatment protocols followed the recommended guidelines.
    METHODS: This retrospective study reviewed antenatal and postnatal (48 h) data of women (n = 150) who had a live birth at Bathurst Hospital between 01/01/2020 and 30/04/2020. Demographic data, risk factors for anaemia in pregnancy, antenatal bloods, treatments provided in trimesters one (T1), two (T2) and three (T3), and postpartum complications were recorded. These were compared to the Australian Red Cross Guidelines (ARCG) using descriptive statistics.
    RESULTS: Of the women with screening data available (n = 103), they were mostly aged 20-35yrs (79.6%), 23.3% were obese, 97.1% were iron deficient, 17% were anaemic and only a few (5.3%) completed the full pregnancy screening as recommended by the ARCG while a majority completed only partial screenings specifically Hb levels in T1 (56.7%), T2 (44.7%) and T3 (36.6%). Compliance to oral iron was largely undocumented, but constipation was a common side effect among the women. IV iron was administered in 14.0% of women, approximately 1.75x higher than the recommended rate.
    CONCLUSIONS: This study provided useful information about compliance to screening and treatment guidelines for anaemia in pregnancy. We identified the need for improved documentation and communication between various health providers to ensure adequate antenatal care to prevent maternal complications during pregnancy. This will improve patient care and encourage further developments in maternal care, bridging the rural health gap.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    引言妊娠引起各种生理变化,经常导致并发症。妊娠期生理性贫血,由于血浆体积和促红细胞生成素水平增加,构成重大健康风险。与妊娠期贫血相关的不良结局包括孕产妇和围产期死亡率,早产,低出生体重。药物利用研究旨在促进合理用药,以改善健康结果。美国食品和药物管理局(FDA)根据致畸风险对药物进行分类,为临床医生提供指导。这项研究旨在分析阿南德地区孕妇贫血的处方趋势和FDA风险类别。材料和方法该研究获得了机构伦理批准,并涉及从2021年12月至2023年3月在产前诊所就诊的816名孕妇。参与者提供知情同意书,数据收集包括每三个月的血红蛋白(Hb)水平,将参与者分为贫血组(Hb<11gm/dL)和非贫血组。记录了处方药物,并使用世卫组织基本药物清单(WHO-EML)和国家基本药物清单-2022(NLEM-2022)对其必要性进行了评估。FDA药物风险类别用于评估药物安全性。进行描述性和统计分析。结果妊娠期贫血患病率为62.50%~65.93%,总体平均值为64.42%。铁和叶酸的补充在三个月内是显著的,处方率不同。钙补充显示波动,在妊娠后期有100%的处方率。在整个怀孕期间,贫血孕妇服用抗坏血酸明显。多种维生素是一致的处方,强调其重要性。WHO-EML和NLEM-2022强调了必需的微量营养素,而FDA类别表明药物安全性。结论整个孕期贫血患病率居高不下,强调需要一致的补充。处方模式与循证指南一致,专注于铁和叶酸的补充。钙处方的变化表明了特定于三个月的考虑因素。处方趋势反映了在怀孕期间管理贫血的负责任的方法,强调预防性铁和叶酸治疗。缺乏高风险药物强调了谨慎的处方做法。这项研究为循证药物治疗和孕产妇保健提供了有价值的见解。
    Introduction Pregnancy induces various physiological changes, often leading to complications. Physiological anemia of pregnancy, resulting from increased plasma volume and erythropoietin levels, poses significant health risks. Adverse outcomes associated with anemia during pregnancy include maternal and perinatal mortality, premature delivery, and low birth weight. Drug utilization research aims to promote rational drug use for improving health outcomes. The Food and Drug Administration (FDA) categorizes drugs based on teratogenic risk, providing guidance for clinicians. This study aims to analyze prescription trends and FDA risk categories for anemia in pregnant women in the Anand district. Materials and methods The study received institutional ethics approval and involved 816 pregnant women attending antenatal clinics from December 2021 to March 2023. Participants provided informed consent, and data collection included hemoglobin (Hb) levels at each trimester, categorizing participants into anemic (Hb < 11 gm/dL) and non-anemic groups. Prescribed drugs were recorded, and their essentiality was assessed using the WHO Essential Medicines List (WHO-EML) and the National List of Essential Medicines-2022 (NLEM-2022). FDA drug risk categories were utilized for assessing drug safety. Descriptive and statistical analyses were performed. Results Anemia prevalence across trimesters ranged from 62.50% to 65.93%, with an overall average of 64.42%. Iron and folic acid supplementation were significant across trimesters, with varying rates of prescription. Calcium supplementation showed fluctuations, with 100% prescription rates in later trimesters. Ascorbic acid was significantly prescribed in anemic pregnant women throughout pregnancy. Multivitamins were consistently prescribed, emphasizing their importance. The WHO-EML and NLEM-2022 highlighted essential micronutrients, while FDA categories indicated drug safety. Conclusion Anemia prevalence remained high throughout pregnancy, emphasizing the need for consistent supplementation. Prescription patterns aligned with evidence-based guidelines, focusing on iron and folic acid supplementation. Variations in calcium prescription suggest trimester-specific considerations. Prescription trends reflect a responsible approach to managing anemia during pregnancy, emphasizing prophylactic iron and folic acid therapy. The absence of high-risk medications underscores cautious prescribing practices. This study contributes valuable insights into evidence-based pharmacotherapy and maternal health care.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    该研究旨在评估超声处理和琥珀酰化对功能的影响,铁结合,生理化学,鹰嘴豆蛋白浓缩物的细胞矿物质摄取功效。琥珀酰化导致持水能力(WHC)的显着改善(25.47%),持油能力(OHC)(31.38%),鹰嘴豆蛋白-铁复合物的溶解度(5.80%)。矿物质生物有效性显著提高4.41%,细胞矿物质摄取显着增加(64.64%),留存率(36.68%),和交通运输(27.96%)。琥珀酰化鹰嘴豆蛋白-铁复合物的铁蛋白含量显着增加了66.31%。此外,超声处理和琥珀酰化相结合的双重修饰方法使蛋白质-铁复合物的粒径降低了83.25%。它还导致SH(巯基)含量显着提高了51.5%,表面疏水性提高了48.92%。矿物质生物利用度和细胞矿物质摄取,保留,通过双重修饰进一步增强了运输。在应用方面,在基于水果的冰沙中添加单一和双重修饰的鹰嘴豆蛋白-铁复合物显示出在感官属性方面的积极接受。总的来说,琥珀酰化和超声处理鹰嘴豆蛋白-铁复合物的组合方法显示出增强生理化学和技术功能特性的有希望的策略,细胞矿物质吸收,以及纯素食品的开发。
    The research aimed to evaluate the effect of ultrasonication and succinylation on the functional, iron binding, physiochemical, and cellular mineral uptake efficacy of chickpea protein concentrate. Succinylation resulted in significant improvements in the water-holding capacity (WHC) (25.47 %), oil-holding capacity (OHC) (31.38 %), and solubility (5.80 %) of the chickpea protein-iron complex. Mineral bioavailability significantly increased by 4.41 %, and there was a significant increase in cellular mineral uptake (64.64 %), retention (36.68 %), and transport (27.96 %). The ferritin content of the succinylated chickpea protein-iron complex showed a substantial increase of 66.31%. Furthermore, the dual modification approach combining ultrasonication and succinylation reduced the particle size of the protein-iron complex with a substantial reduction of 83.25 %. It also resulted in a significant enhancement of 51.5 % in the SH (sulfhydryl) content and 48.92 % in the surface hydrophobicity. Mineral bioavailability and cellular mineral uptake, retention, and transport were further enhanced through dual modification. In terms of application, the addition of single and dual-modified chickpea protein-iron complex to a fruit-based smoothie demonstrated positive acceptance in sensory attributes. Overall, the combined approach of succinylation and ultrasonication to the chickpea protein-iron complex shows a promising strategy for enhancing the physiochemical and techno-functional characteristics, cellular mineral uptake, and the development of vegan food products.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Clinical Trial Protocol
    背景:世界卫生组织建议在超过40%的人口出现贫血的国家,对6-23个月的儿童普遍补充铁。常规的亚铁盐由于患有炎症的儿童的低口服吸收而具有低功效。血红素铁更具有生物可利用性,它的吸收可能不会因炎症而减少。这项研究旨在比较补充12周后每天补充血红素铁和硫酸亚铁对血红蛋白浓度和血清铁蛋白浓度的影响。
    方法:这将是双臂,随机对照试验。6-12个月的冈比亚贫血儿童将在预定的地理区域内招募,并由训练有素的现场工作人员招募。符合条件的参与者将使用1:1的比例在置换块内进行每日补充,为期12周,使用10.0mg元素铁作为血红素或硫酸亚铁。临床团队将每天评估安全性结果,例如腹泻和感染相关的不良事件(参见Bah等人。附加文件4_不良事件eCRF)。线性回归将用于分析连续结果,使用对数变换来根据需要对残差进行归一化。二元结果将通过二项回归或逻辑回归进行分析,初步分析将通过修改后的意向治疗(即,那些被随机分组并摄入至少一个补充剂量的铁),使用多个估算来替换丢失的数据。将根据基线协变量调整效应估计值(C反应蛋白,α-1-酸糖蛋白,血红蛋白,铁蛋白,可溶性转铁蛋白受体)。
    结论:本研究将确定在6-12个月的贫血儿童中,治疗性补充血红素铁是否比常规硫酸亚铁更有效地提高血红蛋白和铁蛋白浓度。
    背景:泛非临床试验注册PACTR202210523178727。
    BACKGROUND: The World Health Organization recommends universal iron supplementation for children aged 6-23 months in countries where anaemia is seen in over 40% of the population. Conventional ferrous salts have low efficacy due to low oral absorption in children with inflammation. Haem iron is more bioavailable, and its absorption may not be decreased by inflammation. This study aims to compare daily supplementation with haem iron versus ferrous sulphate on haemoglobin concentration and serum ferritin concentration after 12 weeks of supplementation.
    METHODS: This will be a two-arm, randomised controlled trial. Gambian children aged 6-12 months with anaemia will be recruited within a predefined geographical area and recruited by trained field workers. Eligible participants will be individually randomised using a 1:1 ratio within permuted blocks to daily supplementation for 12 weeks with either 10.0 mg of elemental iron as haem or ferrous sulphate. Safety outcomes such as diarrhoea and infection-related adverse events will be assessed daily by the clinical team (see Bah et al. Additional file 4_Adverse event eCRF). Linear regression will be used to analyse continuous outcomes, with log transformation to normalise residuals as needed. Binary outcomes will be analysed by binomial regression or logistic regression, Primary analysis will be by modified intention-to-treat (i.e., those randomised and who ingested at least one supplement dose of iron), with multiple imputations to replace missing data. Effect estimates will be adjusted for baseline covariates (C-reactive protein, alpha-1-acid glycoprotein, haemoglobin, ferritin, soluble transferrin receptor).
    CONCLUSIONS: This study will determine if therapeutic supplementation with haem iron is more efficacious than with conventional ferrous sulphate in enhancing haemoglobin and ferritin concentrations in anaemic children aged 6-12 months.
    BACKGROUND: Pan African Clinical Trial Registry PACTR202210523178727.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    缺铁性贫血(IDA)和糖尿病(DM)是最常见的疾病,糖尿病患者更容易患IDA。因此,这项研究的主要目的是调查糖尿病患者与IDA之间的关系,即每天和每隔一天服用铁丸以减少与之相关的影响。91名参与者被招募并随机分为两组,与72例患者的最终分析队列。主要关注血清Hb和铁蛋白水平的变化。筛查阶段持续了24周,导致72名符合条件的参与者符合进入研究的标准。此外,该研究检测了缺铁患者治疗后Hb和HbA1C水平的变化.各组间Hb和铁蛋白水平差异无统计学意义(分别为P=0.096和P=0.500)。治疗前后HbA1C与Hb水平呈正相关(r2=0.187)。本研究的结果表明,尽管使用口服铁补充剂的有效性在增加血红蛋白和铁蛋白方面没有显着差异,每隔一天使用一次口服铁,比每天使用口服铁更有效,在这项研究中,像其他研究一样,此结果得出结论,HbA1C与Hb呈负相关,并检查糖尿病患者的HbA1C状况,首先应考虑Hb水平。
    Iron deficiency anaemia (IDA) and diabetes mellitus (DM) are most prevalent disease, that diabetic patients are more prone to IDA. Therefore, the main aim of this study was to investigate the relationship between patients with diabetes and IDA in relation to taking iron pills daily and every other day to reduce the effects related to it. Ninety-one participants were enroled and randomly divided into two groups, with a final analysis cohort of 72 patients. The primary focus was on changes in serum Hb and Ferritin levels. The screening phase lasted 24 weeks, leading to 72 eligible participants meeting the criteria for entry into the study. Additionally, the study examined alternations in Hb and Hb A1C levels after treating patients with iron deficiency. The Hb and ferritin level contrasts between groups were not significant (P = 0.096 and P = 0.500, respectively). The relationship between Hb A1C and Hb levels before and after treatment was positive and significant (r 2 = 0.187). The results of the present study show that although the effectiveness of using oral iron supplements did not have a significant difference in terms of increasing haemoglobin and ferritin, the use of oral iron once every other day was more effective than the use of oral iron every day, and also in this study Like other studies, this result concluded that there is a negative correlation between Hb A1C and Hb, and to check the status of Hb A1C in diabetics, the level of Hb should be considered first.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    The objective of this study was to investigate the potential associations between serum iron levels, dietary iron intake, and iron supplementation, and the prevalence of metabolic syndrome (MetS) in adolescents A cross-sectional analysis was conducted, utilizing data from adolescents participating in the 2003-2018 cycle of the National Health and Nutrition Examination Survey (NHANES). Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) pertaining to serum iron, dietary iron, and iron supplementation were derived through multivariate logistic regression models. Additionally, a restricted cubic spline (RCS) regression model was applied to explore the nonlinear relationship between dietary iron and serum iron concerning MetS. The study encompassed 4858 American adolescents aged 12 to 19, among whom 413 (8.5%) manifested MetS. The study cohort exhibited an average age of 15.52 years, comprising 2551 males (52.51%) and 2307 females (47.49%). Relative to individuals in the lowest serum iron quartile, those in the highest quartile for serum iron (OR = 0.33, 95% CI 0.21-0.50), the highest quartile for dietary iron (OR = 0.53, 95% CI 0.32-0.89), and those utilizing iron supplements (OR = 0.61, 95% CI 0.37-0.99) evinced a diminished prevalence of MetS, even post adjustment for potential confounding variables. A non-linear relationship was discerned between serum iron and MetS, exhibiting a statistically significant negative correlation when serum iron concentrations exceeded the inflection point (serum iron = 8.66 µmol/L, P for nonlinear < 0.001). This investigation reveals that higher levels of serum iron, increased dietary iron intake, and the use of iron supplements are linked to a lower prevalence of MetS in US adolescents. These findings suggest that dietary modifications could play a role in promoting the health of adolescents.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: English Abstract
    Cancer related anemia (CRA) is a common side effect in patients with tumors, the incidence of which is related to tumor type, treatment regimen, the duration of chemotherapy, etc. The pathogenesis of CRA has not been fully defined. CRA may lead to chemotherapy dose reduction or may even delay chemotherapy. Patients with CRA require red blood cell transfusion, thus increasing the treatment cost, reducing the efficiency of chemotherapy and the patient\'s quality of life, and shortening the survival time. The main treatments of CRA include red blood cell transfusion, iron supplements, erythropoietin, and so on. Based on recent literature and clinical studies, the expert committee of the China Anti-Cancer Association drew up the consensus on the diagnosis and treatment of anemia related to tumor in China (2023 edition). The 2023 consensus incorporates the latest evidence-based medicine evidence and Traditional Chinese Medicine related content and aims to provide more reliable diagnosis and treatment plans for Chinese oncologists to help improve CRA and the quality of life in patients with cancer.
    肿瘤相关贫血为肿瘤患者常见的不良反应,其发生率与肿瘤类型、治疗方案和周期疗程等均有关,其发病机制尚未明确。肿瘤相关贫血有可能导致化疗药物剂量降低、化疗时间延迟、需要输注红细胞等,从而增加患者的治疗费用、降低化疗效果和患者的生存质量、缩短生存时间。肿瘤相关贫血的主要治疗包括输注红细胞、促红细胞生成治疗和补充铁剂等。基于文献及临床研究的发展,中国抗癌协会肿瘤临床化疗专业委员会和肿瘤支持治疗专业委员会组织专家制定了《中国肿瘤相关贫血诊治专家共识(2023版)》,相较于《中国肿瘤化疗相关贫血诊治专家共识(2019年版)》,2023版共识采用了新的循证医学证据、纳入了中医相关内容,旨在为肿瘤相关贫血患者提供更为合理的诊疗方案,从而帮助患者改善肿瘤相关贫血,提高生存质量。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    本研究旨在根据手术类型评估全膝关节置换术(TKA)的输血率和血液管理药物使用率的年度趋势,并分析TKA术后输血的危险因素。
    使用2008年1月至2019年10月之间的797,106个主要和修订TKA的韩国国民保险索赔数据库,有关患者特征的数据,合并症,利用输血,并收集血液管理药物。根据手术类型将患者分为三组:原发性,修订版,同时双侧TKA。比较输血率和血液管理药物(术中氨甲环酸[TXA]和术前补铁)的利用率,并评估输血的危险因素。
    排除不准确的数据后,730,554关节成形术(636,292主要,10,540修订版,并同时确定了41,861个双边TKA)。原发性输血率,修订版,2019年同期双边TKA为64.0%,67.7%,和68.9%,分别,与83.2%相比显著下降,88.0%,2008年分别为92.5%(p<0.001)。相反,术中TXA和术前补铁的利用率从4.6%和13.8%显著提高,分别,2008年分别为52.4%和27.0%,分别,2019年(p<0.001)。术中TXA和术前补铁的使用显着降低了TKA后输血的风险(比值比[OR],0.20;p<0.001和OR,0.71;p<0.001)。
    在2008年至2019年期间,韩国TKA后的输血率从83.5%逐渐下降至64.5%,这与血液管理药物的使用增加相对应。因此,应始终重视患者的血液管理,以降低TKA术后输血率.
    UNASSIGNED: This study aimed to evaluate the annual trends of transfusion rates and utilization of blood management agents in total knee arthroplasty (TKA) based on the operation type and to analyze the risk factors of transfusion after TKA.
    UNASSIGNED: Using the Korean National Insurance claims database of 797,106 primary and revision TKAs between January 2008 and October 2019, data on the patients\' characteristics, comorbidities, utilization of transfusion, and blood management agents were collected. The patients were categorized into three groups based on the operation type: primary, revision, and simultaneous bilateral TKA. The transfusion rate and utilization of blood management agents (intraoperative tranexamic acid [TXA] and preoperative iron supplements) were compared, and the risk factors for transfusion were evaluated.
    UNASSIGNED: After excluding the inaccurate data, 730,554 arthroplasties (636,292 primary, 10,540 revision, and 41,861 simultaneous bilateral TKAs) were identified. The transfusion rates of primary, revision, and simultaneous bilateral TKAs in 2019 were 64.0%, 67.7%, and 68.9%, respectively, which were significantly decreased compared with 83.2%, 88.0%, and 92.5% in 2008, respectively (p < 0.001). Conversely, the utilization of intraoperative TXA and preoperative iron supplements was significantly increased from 4.6% and 13.8%, respectively, in 2008 to 52.4% and 27.0%, respectively, in 2019 (p < 0.001). The utilization of intraoperative TXA and preoperative iron supplements significantly lowered the risk of transfusion after TKA (odds ratio [OR], 0.20; p < 0.001 and OR, 0.71; p < 0.001).
    UNASSIGNED: The transfusion rate after TKA decreased gradually from 83.5% to 64.5% between 2008 and 2019 in South Korea corresponding with the increased utilization of blood management agents. Therefore, consistent attention to patient blood management should be emphasized to reduce the transfusion rate after TKA.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    为贫血儿童开具的铁补充剂可能会导致牙齿染色。在接触铁补充剂后,预防乳牙染色的可能方法需要一个小时。
    进行该研究的目的是评估牙釉质表面涂层对乳牙中含铁补充剂的染色能力的影响。
    这是一项体外实验研究。
    将完整牙冠的一百四十四个初级门牙依次编号,并随机分为四个主要组,每组36个样品,接受不同的釉质表面涂层,例如没有表面涂层,MI氟化物清漆™,GCG-coatPlus™和GC-Equia®-forte-coat。每组又分为两组,即A(健全的牙齿)和B(人工脱矿的牙齿)。将所有样品浸入含有10ml铁补充剂的250ml人工唾液中,使铁浓度为100mg。在基线和90天测量牙齿的阴影,使用VITAEasyshade®V数字分光光度计。使用Kruskal-Wallis检验和Mann-WhitneyU检验对数据进行统计分析。通过SPSS23进行描述性和推断性统计分析。
    当使用GC-Equia®-forte-coat作为具有0.017的pvalue的搪瓷表面涂层时,发现在第90天结束时,声音样品中的总体颜色变化显著较小。在脱矿质样品中,当MIVarnish™用作釉质表面涂层时,总颜色变化在第90天结束时最小,P=0.042。
    GC-Equia®-forte-coat,MIVarnish™和GC-G-coat-plus™可用作预防或预防措施,以最大程度地减少牙齿的污染。90天结束时GC-Equia®-forte-coat的颜色变化量最少,然后是MIvarnish™,GCGcoatPlus™和对照组。
    UNASSIGNED: Iron supplements prescribed to anemic children may results in teeth staining. Possible methods for preventing staining of primary teeth following exposure to iron supplements are need of an hour.
    UNASSIGNED: This study was conducted with the aim to assess effect of enamel surface coating on staining capability of iron containing supplements in primary teeth.
    UNASSIGNED: This is an in vitro Experimental study.
    UNASSIGNED: Hundred and forty-four primary incisors with intact crowns were sequentially numbered and randomly divided into four main groups of 36 samples receiving different enamel surface coating such as no surface coating, MI fluoride varnish™, GC G-coat Plus™ and GC-Equia®-forte-coat. Each group was subdivided into two groups, namely A (sound teeth) and B (artificially demineralized teeth). All the samples were immersed in 250 ml artificial saliva containing 10 ml of iron supplement to make the iron concentration 100 mg. The shade of the teeth was measured at baseline and at 90 days, using VITA Easy shade® V digital spectrophotometer. The data was statistically analyzed using the Kruskal-Wallis test and Mann-Whitney U test. Descriptive and inferential statistical analyses was made via SPSS 23.
    UNASSIGNED: Overall color change was found to be significantly less at the end of 90th day in sound samples when GC-Equia®-forte-coat was used as an enamel surface coating with pvalue of 0.017. In demineralized samples the overall color change was least at the end of 90th day when MI Varnish™ used as an enamel surface coating with P = 0.042.
    UNASSIGNED: GC-Equia®-forte-coat, MI Varnish™ and GC-G-coat-plus™ can be used as a preventive or a precautionary measure to minimizes the staining of teeth. The amount of color change at the end of 90 days with GC-Equia®-forte-coat was least followed by MI varnish™, GC G coat Plus™ and control group.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号